- Home
- EMF vs TLSI Comparison
EMF vs TLSI Comparison
Compare EMF & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMF
- TLSI
- Stock Information
- Founded
- EMF 1987
- TLSI 2010
- Country
- EMF United States
- TLSI United States
- Employees
- EMF N/A
- TLSI N/A
- Industry
- EMF Finance/Investors Services
- TLSI Medical Specialities
- Sector
- EMF Finance
- TLSI Health Care
- Exchange
- EMF Nasdaq
- TLSI Nasdaq
- Market Cap
- EMF 254.5M
- TLSI 244.3M
- IPO Year
- EMF N/A
- TLSI N/A
- Fundamental
- Price
- EMF $17.72
- TLSI $4.65
- Analyst Decision
- EMF
- TLSI Strong Buy
- Analyst Count
- EMF 0
- TLSI 4
- Target Price
- EMF N/A
- TLSI $11.13
- AVG Volume (30 Days)
- EMF 29.3K
- TLSI 127.1K
- Earning Date
- EMF 01-01-0001
- TLSI 11-13-2025
- Dividend Yield
- EMF 6.16%
- TLSI N/A
- EPS Growth
- EMF N/A
- TLSI N/A
- EPS
- EMF N/A
- TLSI N/A
- Revenue
- EMF N/A
- TLSI $35,990,000.00
- Revenue This Year
- EMF N/A
- TLSI $56.71
- Revenue Next Year
- EMF N/A
- TLSI $52.25
- P/E Ratio
- EMF N/A
- TLSI N/A
- Revenue Growth
- EMF N/A
- TLSI 45.50
- 52 Week Low
- EMF $10.58
- TLSI $3.42
- 52 Week High
- EMF $12.67
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- EMF 65.21
- TLSI 44.30
- Support Level
- EMF $16.82
- TLSI $4.50
- Resistance Level
- EMF $18.01
- TLSI $4.81
- Average True Range (ATR)
- EMF 0.27
- TLSI 0.23
- MACD
- EMF 0.04
- TLSI -0.04
- Stochastic Oscillator
- EMF 77.39
- TLSI 27.66
About EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company. It seeks long-term capital appreciation by investing, under normal market conditions, at least 80% of its net assets in emerging country equity securities. It invests in various sectors such as Pharmaceuticals, Beverages, Broadline Retail, Metals &Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, insurance, Entertainment, and others.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.